Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

EBioMedicine

Volumn 40, Issue , 2019, Pages 574-582

  Hershberger, Ellie ^a   Sloan, Susan ^a   Narayan, Kristin ^a   Hay, Catherine A ^a   Smith, Patrick ^b   Engler, Frank ^b   Jeeninga, Rienk ^c   Smits, Saskia ^c   Trevejo, Jose ^a   Shriver, Zach ^a   Oldach, David ^a  

^a VISTERRA INC   (United States)

^b CERTARA   (United States)

^c ViroClinics Biosciences   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPHENHYDRAMINE; IBUPROFEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY VIS410; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PSEUDOEPHEDRINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIS410 MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION AND FOLLOW UP; FATIGUE; FEMALE; FEVER; GASTRITIS; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HEADACHE; HELICOBACTER INFECTION; HEMAGGLUTINATION INHIBITION; HEMAGGLUTINATION INHIBITION TEST; HEMISPHERE; HUMAN; HYPERTENSION; HYPOXEMIA; IC50; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H3N2); INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE SPASM; MYALGIA; NAUSEA AND VOMITING; PHARMACIST; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SORE THROAT; STOMACH ULCER; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT INFECTION; VIROLOGY; VIRUS CULTURE; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; YOUNG ADULT; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECT; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INFLUENZA; INFLUENZA A VIRUS; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; VIRAL LOAD; VIRUS SHEDDING;

EID: 85059640945     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2018.12.051     Document Type: Article

References (34)

1. WHO, Guidelines for pharmacological management of Pandemic influenza A(H1N1) 2009 and other influenza viruses. Revised, Feb. 2010.
2. Hayden, F.G., Sugaya, N., Hirotsu, N., et al. Baloxavir Marboxil for Uncomplicated Influenza in adults and Adolescents. N Engl J Med 379:10 (2018), 913–923.
3. Reed, C., Chaves, S.S., Daily Kirley, P., et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One, 10(3), 2015, e0118369.
4. Luke, T.C., Kilbane, E.M., Jackson, J.L., Hoffman, S.L., Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 145:8 (2006), 599–609.
5. Hung, I.F., To KK, Lee, C.K., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza a (H1N1) 2009 virus infection. Clin Infect Dis Off Publ Infect Dis Soc Am 52:4 (2011), 447–456.
6. Hung, I.F.N., To KKW, Lee, C.K., et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144:2 (2013), 464–473.
7. Beigel, J.H., Tebas, P., Elie-Turenne, M.C., et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 5:6 (2017), 500–511.
8. Wollacott, A.M., Boni, M.F., Szretter, K.J., et al. Safety and Upper respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 support Treatment and Prophylaxis based on Population Modeling of Seasonal Influenza a Outbreaks. EBioMedicine 5 (2016), 147–155.
9. Trevejo, J.M., SEKS, Sloan, Bedard, S., Hay, C.A., Safety and efficacy of the monoclonal antibody VIS410 in a human volunteer challenge model of infection with an H1N1 Influenza A virus. International Conference of Respiratory and Critical Care Medicine, 2016, American Thoracic Society, San Francisco, CA.
10. Powers, J.H. 3rd, Bacci, E.D., Guerrero, M.L., et al. Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO(c)) scores in Influenza-positive patients. Value Health J Int Soc Pharmacoeconomics Outcome Res 21:2 (2018), 210–218.
11. Powers, J.H., Guerrero, M.L., Leidy, N.K., et al. Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis, 16, 2016, 1.
12. Garten, R., Blanton, L., Elal, A.I.A., et al. Update: Influenza activity in the United States during the 2017-18 season and Composition of the 2018-19 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 67:22 (2018), 634–642.
13. Hammond, A., Laurenson-Schafer, H., Marsland, M., et al. Review of the 2017-2018 influenza season in the Northern Hemisphere. World Health Organization Weekly Epidemiological Record, 93, 2018, 429–444.
14. The Lancet Infectious D, How to be ready for the next influenza pandemic. Lancet Infect Dis, 18(7), 2018, 697.
15. The Lancet Infectious D, Plotting a route to a universal influenza vaccine. Lancet Infect Dis, 18(5), 2018, 475.
16. Popova, L., Smith, K., West, A.H., et al. Immunodominance of antigenic site B over site a of hemagglutinin of recent H3N2 influenza viruses. PLoS One, 7(7), 2012, e41895.
17. Shah, D.K., Betts, A.M., Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5:2 (2013), 297–305.
18. Abbo, L., Quartin, A., Morris, M.I., et al. Pulmonary imaging of pandemic influenza H1N1 infection: relationship between clinical presentation and disease burden on chest radiography and CT. Br J Radiol 83:992 (2010), 645–651.
19. Taubenberger, J.K., Morens, D.M., The pathology of influenza virus infections. Annu Rev Pathol 3 (2008), 499–522.
20. Erbelding, E.J., Post, D.J., Stemmy, E.J., et al. A Universal Influenza Vaccine: the Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis 218:3 (2018), 347–354.
21. Coughlan, L., Palese, P., Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine. Cell Host Microbe 24:1 (2018), 18–24.
22. Nachbagauer, R., Palese, P., Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. Curr Opin Immunol 53 (2018), 51–57.
23. Andrews, S.F., Graham, B.S., Mascola, J.R., AB, McDermott, Is it possible to develop a “Universal” Influenza virus vaccine? immunogenetic considerations underlying B-cell biology in the development of a pan-subtype influenza a vaccine targeting the Hemagglutinin stem. Cold Spring Harb Perspect Biol, 2018, 10(7).
24. Crowe, J.E. Jr., Is it possible to develop a “Universal” Influenza virus vaccine? potential for a universal influenza vaccine. Cold Spring Harb Perspect Biol, 2018, 10(7).
25. Joyce, M.G., Wheatley, A.K., Thomas, P.V., et al. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza a Viruses. Cell 166:3 (2016), 609–623.
26. Baranovich, T., Jones, J.C., Russier, M., et al. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute respiratory Distress Syndrome. Antimicrob Agents Chemother 60:4 (2016), 2118–2131.
27. Khurana, S., Loving, C.L., Manischewitz, J., et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med, 5(200), 2013, 200ra114.
28. Caskey, M., Schoofs, T., Gruell, H., et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med 23:2 (2017), 185–191.
29. Group PIW, Multi-National PIIST, Davey, R.T. Jr., et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 375:15 (2016), 1448–1456.
30. Ali, S.O., Takas, T., Nyborg, A., et al. Evaluation of MEDI8852, an anti-influenza a monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob Agents Chemother, 62(11), 2018 Oct 24, 10.1128/AAC.00694-18 (Print 2018 Nov, pii: e00694-18).
31. Kallewaard, N.L., Corti, D., Collins, P.J., et al. Structure and function analysis of an antibody recognizing all influenza a subtypes. Cell 166:3 (2016), 596–608.
32. McBride, J.M., Lim, J.J., Burgess, T., et al. Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human Influenza A virus challenge model. Antimicrob Agents Chemother, 2017, 61(11).
33. Lim, J.L., Nilsson, A.C., Silverman, M., Mironova, N., Kulkarni, P., McBride, J.M., The CRANE study: A phase 2b randomized, double-blind, placebo-controlled trial of monoclonal antibody MHAA4549A combined with oseltamivir versus oseltamivir alone for treatment of severe influenza A infection. 2018, 28th ECCMID, 2018.
34. Van Baalen, C.A., Els, C., Sprong, L., van Beek, R., van der Vries, E., Osterhaus, A.D., et al. Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture. J Clin Microbiol 52:5 (2014 May), 1672–1677, 10.1128/JCM.03575-13 Epub 2014 Mar 12 24622097.